Search
After a solid organ transplant, monitoring levels of donor-derived cell-free DNA (dd-cfDNA) can provide valuable insights into the organ's health and function1. The One Lambda Devyser Accept cfDNA single-tube NGS assay is a minimally invasive solution that helps provide precise and reliable results, to monitor cfDNA following kidney transplantation.
Assay key features and benefits
- Dual donor distinction: Can support the accurate assignment of origin of detected cfDNA in patients with two kidney transplants
- Highly sensitive: Enables the detection of cfDNA at levels as low as 0.1%2
- Robust indel design: Utilizes 50 highly informative and population-independent indel markers, the assay detects and differentiates between two genetically distinct donors for each recipient
- Unified workflow: Simplify your laboratory processes with a streamlined workflow for both screening and monitoring assays with as little as 45 minutes hands-on time
- Straightforward data analysis: The user-friendly, dedicated software simplifies data analysis and bioinformatics, and the built-in quality controls facilitate confidence in results
What is the One Lambda Devyser Accept cfDNA Assay?
Minimally invasive and highly robust method for detecting dd-cfDNA
Accept cfDNA is an NGS assay designed to detect and analyze circulating dd-cfDNA in post-transplant human plasma samples. Its unique indel design allows for accurate results, reduces amplification and sequencing errors. Combined with an efficient workflow, Accept cfDNA is the ideal tool for post-transplant monitoring and provides early time to result when run in your own in house HLA lab.
One Lambda Deveyser Accept cfDNA Assay is now IVDR certificated for dual donor testing
Dual donor testing using One Lambda Devyser Accept cfDNA can support accurately assigning the origin of detected cfDNA from donors in patients with two kidney transplants.
Current testing methods may inaccurately detect elevated levels of cfDNA from the non-functioning graft and can be falsely associated with the second graft in patients with two kidney transplants. These testing methods could be subjected to varying influence from the first graft creating additional complications in the post-transplant monitoring of graft function. The One Lambda Devyser Accept cfDNA test is highly sensitive and has been shown to reliably detect and differentiate cfDNA in patients with two kidney transplants.2
How does the One Lambda Devyser Accept cfDNA Assay work?
Efficient workflow and reliable results for post-transplant monitoring
The One Lambda Devyser Accept cfDNA assay was developed by leading transplant specialists to deliver efficiency and ease of use with minimal hands-on time. Labs can receive next-day results from sample to report allowing for timely results. Our dedicated software simplifies data analysis and bioinformatics capabilities, allowing for easy patient tracking in a single location. With the ability to import analyzed data into Histotrac, all information is consolidated, providing clear visibility of trends.
Fig. 1. Workflow.
Resources
Support
Advanced molecular transplant monitoring solutions with the Devyser and Thermo Fisher Scientific collaboration
The collaboration between Devyser and Thermo Fisher Scientific combines expertise and resources to offer enhanced and cutting-edge molecular kidney transplant monitoring capabilities to transplant programs, HLA labs, and transplant clinicians. Backed by Thermo Fisher Scientific's robust commercial infrastructure, our collaboration helps support reliable, accurate, and high-quality testing solutions for healthcare providers worldwide.
Product is IVDR certified but not 510(k) cleared. Availability of the product in each country depends on local regulatory marketing authorization status. Dvysr is a trademark of Devyser AB. Not all products are available in all countries. Please consult your local sales representative for details.